Pacira BioSciences, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2021 | — | $650.8M | $66.7M |
| Jun 2021 | — | $687.2M | $105.8M |
| Sep 2021 | — | $718.6M | $134.0M |
| Dec 2021 | — | $730.4M | $585.6M |
| Mar 2022 | — | $709.6M | $226.8M |
| Jun 2022 | — | $756.6M | $122.1M |
| Sep 2022 | — | $770.1M | $109.4M |
| Dec 2022 | $689.5M | $775.0M | $104.1M |
| Mar 2023 | — | $768.0M | $35.5M |
| Jun 2023 | — | $808.0M | $86.8M |
| Sep 2023 | — | $831.6M | $99.1M |
| Dec 2023 | $522.4M | $870.1M | $153.3M |
| Mar 2024 | — | $892.2M | $184.1M |
| Jun 2024 | — | $879.3M | $247.1M |
| Sep 2024 | — | $749.6M | $246.0M |
| Dec 2024 | $383.5M | $778.3M | $276.8M |
| Mar 2025 | $583.4M | $798.5M | $283.6M |
| Jun 2025 | $580.5M | $757.8M | $300.5M |
| Sep 2025 | $376.7M | $727.2M | $147.6M |
| Dec 2025 | $372.2M | $693.1M | $158.5M |